title: Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study.
abstract: OBJECTIVE
  In 1986 a prospective, randomized, multi-centre trial for evaluation of neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in the treatment of advanced squamous cell carcinoma of the head and neck was initiated. As survival in this group of patients is poor the purpose was to find a possible survival benefit of the chemotherapy in addition to radiotherapy compared to radiotherapy only.
  
  
  METHODS
  Four-hundred sixty-one patients from Denmark, Norway and Sweden with tumors in oral cavity, oropharynx, hypopharynx and larynx were randomized to receive either standard treatment (radiotherapy or radiotherapy followed by surgery) or neoadjuvant chemotherapy followed by standard treatment. Chemotherapy included three courses of cisplatin 100 mg/m2 i.v. infusion on day 1 followed by 5-fluorouracil 1000 mg/m2 per day continuous i.v. infusion for 120 hours. Radiotherapy 64-70 Gy in 2 Gy per fraction, 5 times/week, was given to patients in both treatment arms.
  
  
  RESULTS
  Response rate was 71% for patients randomized to chemotherapy-radiotherapy and 66% for patients randomized to standard treatment (not statistically significant). Residual tumors were excised if possible. After surgery 62% of the patients randomized to chemotherapy-radiotherapy and 60% of the patients in the standard treatment group were clinically tumor free.
  
  
  CONCLUSIONS
  No statistically significant benefit in survival was observed for patients treated with neoadjuvant chemotherapy followed by radiotherapy. Nor was there any impact of chemotherapy on the number of patients achieving loco-regional tumor control after primary treatment.
authors.affiliation: Department of Oncology, Huddinge University Hospital, Sweden.
authors.forename: F
authors.initials: F
authors.lastname: Lewin
authors.forename: L
authors.initials: L
authors.lastname: Damber
authors.forename: H
authors.initials: H
authors.lastname: Jonsson
authors.forename: T
authors.initials: T
authors.lastname: Andersson
authors.forename: A
authors.initials: A
authors.lastname: Berthelsen
authors.forename: A
authors.initials: A
authors.lastname: Biörklund
authors.forename: E
authors.initials: E
authors.lastname: Blomqvist
authors.forename: J F
authors.initials: JF
authors.lastname: Evensen
authors.forename: H S
authors.initials: HS
authors.lastname: Hansen
authors.forename: O
authors.initials: O
authors.lastname: Hansen
authors.forename: O
authors.initials: O
authors.lastname: Jetlund
authors.forename: C
authors.initials: C
authors.lastname: Mercke
authors.forename: H
authors.initials: H
authors.lastname: Modig
authors.forename: M
authors.initials: M
authors.lastname: Overgaard
authors.forename: B
authors.initials: B
authors.lastname: Rosengren
authors.forename: J
authors.initials: J
authors.lastname: Tausjö
authors.forename: U
authors.initials: U
authors.lastname: Ringborg
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D002945:Cisplatin; D005472:Fluorouracil